Oppenheimer initiated coverage on Penumbra with a new price target
$PEN
Medical/Dental Instruments
Health Care
Oppenheimer initiated coverage of Penumbra with a rating of Outperform and set a new price target of $275.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/14/2025 | $320.00 | Buy | BofA Securities |
| 1/21/2025 | $305.00 | Buy | UBS |
| 12/17/2024 | $275.00 | Outperform | Oppenheimer |
| 12/11/2024 | $190.00 → $275.00 | Equal Weight → Overweight | Wells Fargo |
| 9/18/2024 | $238.00 | Buy | Stifel |
| 9/3/2024 | $263.00 | Outperform | Leerink Partners |
| 7/31/2024 | $289.00 → $150.00 | Overweight → Equal Weight | Wells Fargo |
| 7/31/2024 | $165.00 → $178.00 | Buy → Neutral | Citigroup |
ALAMEDA, Calif., April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Event: BofA Securities 2025 Health Care ConferenceDate: Tuesday, May 13, 2025Time: 6:00pm ET/3:00pm PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks followi
ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income
ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the
Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i
SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G - Penumbra Inc (0001321732) (Subject)
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income
ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the
ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2 compared to the fourth quarter of 2023.Adjusted revenue1 of $1,200.4 million, excluding the $5.8 million impact of the Italian governme
10-Q - Penumbra Inc (0001321732) (Filer)
8-K - Penumbra Inc (0001321732) (Filer)
DEFA14A - Penumbra Inc (0001321732) (Filer)
BofA Securities initiated coverage of Penumbra with a rating of Buy and set a new price target of $320.00
UBS initiated coverage of Penumbra with a rating of Buy and set a new price target of $305.00
Oppenheimer initiated coverage of Penumbra with a rating of Outperform and set a new price target of $275.00